RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis

Leukemia

Volumn 26, Issue 5, 2012, Pages 1020-1029

  Loder S ^a   Fakler, M ^a   Schoeneberger, H ^b   Cristofanon, S ^b   Leibacher, J ^b   Vanlangenakker, N ^c,d   Bertrand, M J M ^c,d   Vandenabeele, P ^c,d   Jeremias, I ^e   Debatin, K M ^a   Fulda, S ^a,b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c GHENT UNIVERSITY   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

ALL; Apoptosis; IAPs; RIP1

Indexed keywords

CASPASE 8; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETANERCEPT; ETOPOSIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GEMCITABINE; NECROSTATIN 1; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; CHILD; CHILDHOOD CANCER; CLONOGENIC ASSAY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE; MALE; MESENCHYMAL STROMA CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 84860756390     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.353     Document Type: Article

References (32)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Stanulla M, Cario G, Meissner B, Schrauder A, Moricke A, Riehm H et al. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia-a perspective from the BFM Study Group. Blood Cells Mol Dis 2007; 39: 160-163.
3. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124: 511-515.
4. Fulda S. Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia. Br J Haematol 2009; 145: 441-454.
5. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811.
6. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008; 19: 325-331.
7. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
8. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAPtargeted therapies for cancer. Oncogene 2008; 27: 6252-6275.
9. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006; 7: 988-994.
10. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
11. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14: 400-410.
12. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-681.
13. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693.
14. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
15. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G. XIAP expression is posttranscriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer 2010; 55: 260-266.
16. Wuchter C, Richter S, Oltersdorf D, Karawajew L, Ludwig WD, Tamm I. Differences in the expression pattern of apoptosis-related molecules between childhood and adult de novo acute myeloid leukemia. Haematologica 2004; 89: 363-364.
17. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009; 113: 1710-1722.
18. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417-4426.
19. Chao B, Deckwerth TL, Furth PS, Linton SD, Spada AP, Ullman BR et al., inventors; Tetrapeptide Analogs, United States patent PCT/US2005/024700. 2006 16.02.
20. Fulda S, Strauss G, Meyer E, Debatin KM. Functional CD95 ligand and CD95 deathinducing signaling complex in activation-induced cell death and doxorubicininduced apoptosis in leukemic T cells. Blood 2000; 95: 301-308.
21. Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007; 26: 248-257.
22. Mohr A, Zwacka RM, Debatin KM, Stahnke K. A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death Differ 2004; 11: 1153-1154.
23. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC (ed). Synergism and antagonism in chemotherapy. Academic Press: San Diego, USA, 1991, pp 61-102.
24. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimeticinduced apoptosis. Cancer Cell 2007; 12: 445-456.
25. Ting AT, Pimentel-Muinos FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. Embo J 1996; 15: 6189-6196.
26. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
27. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313-321.
28. Loeder S, Drensek A, Jeremias I, Debatin KM, Fulda S. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer 2010; 126: 2216-2228.
29. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009; 69: 2425-2434.
30. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V et al. Smallmolecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009; 11: 743-752.
31. Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Dohner H et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009; 69: 8977-8986.
32. Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia 2009; 23: 467-476.